Drug Trial Radar · NCT06154447
Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis
Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
165
Actual
Start
Dec 12, 2023
Primary completion
Jul 10, 2026
Study completion Jul 10, 2026
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- First posted
- Dec 4, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate safety, tolerability, and pharmacokinetics of VX-828 and VX-828 in triple combination (TC) with Tezacaftor (TEZ)/ VX-118 or TEZ/ deutivacaftor (D-IVA) in healthy participants and VX-828 in combination with D-IVA with or without TEZ in participants with cystic fibrosis (CF).
Conditions
- Cystic Fibrosis
Interventions
VX-828Drug
Suspension for Oral Administration
PlaceboDrug
Suspension for Oral Administration
ItraconazoleDrug
Solution for Oral Administration
MidazolamDrug
Syrup for Oral Administration
TezacaftorDrug
Tablets for Oral Administration
VX-118Drug
Tablets for Oral Administration
PlaceboDrug
Suspension and Tablets for Oral Administration
DeutivacaftorDrug
Tablets for Oral Administration
VX-828Drug
Tablets for Oral Administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Signing of Informed Consent Form (ICF) up to Safety Follow Up (Up to Day 67)
- Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Signing of Informed Consent Form (ICF) up to Safety Follow Up (Up to Day 80)
- Part D: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Signing of Informed Consent Form (ICF) up to Safety Follow Up (Up to Day 80)
- Part E: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Signing of Informed Consent Form (ICF) up to End of Study (Up to Day 111)
- Part C: Maximum Observed Concentration (Cmax) of VX-828 in Plasma in the Absence and Presence of ItraconazoleTime frame: From Day 1 up to Day 71
- Part C: Area Under the Concentration Versus Time Curve (AUC) of VX-828 in Plasma in the Absence and Presence of ItraconazoleTime frame: From Day 1 up to Day 71
- Part C: Maximum Observed Concentration (Cmax) of Midazolam in Plasma in the Absence and Presence of VX-828/TEZ/D-IVATime frame: From Day 1 up to Day 30
- Part C: Area Under the Concentration Versus Time Curve (AUC) of Midazolam in Plasma in the Absence and Presence of VX-828/TEZ/D-IVATime frame: From Day 1 up to Day 30
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Joe DiMaggio Cycstic Fibrosis & Pulmonary Center
Hollywood, Florida
AdventHealth Medical Group Pulmonology at Orlando Ridgewood
Orlando, Florida
Altasciences Clinical Kansas
Overland Park, Kansas
Kentucky Children's Hospital
Lexington, Kentucky
Boston Children's Hospital
Boston, Massachusetts
University of Minnesota -Pulmonology
Minneapolis, Minnesota
Billings Clinic, Pediatric Pulmonary Dept.
Billings, Montana
New York Medical College
Hawthorne, New York
ProMedica Toledo Children's Hospital & ProMedica Central Physicians, LLC
Toledo, Ohio
Cook Children's Pulmonology
Fort Worth, Texas
University of Utah Hospital - Pulmonology
Salt Lake City, Utah
Vermont Lung Center
Colchester, Vermont
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.